Retinal vascular occlusion affects the eye, specifically the retina. The retina is the light-sensitive layer of tissue that lines the back of your eye. It’s covered with special cells called rods and ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

Please provide your email address to receive an email when new articles are posted on . WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Sharon Fekrat, MD, FACS, FASRS, discusses a real ...

NEW YORK, July 30 (Reuters) - Roche Holding AG's eye disease drug Lucentis proved effective in helping to improve vision in patients suffering from a condition known as central retinal vein occlusion, ...

COVID-19 infection may be boosting the numbers of a rare ocular condition in which vision is threatened when veins in the retina are blocked, eye specialists in Southern California report. Risk of ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...

LOS ANGELES, July 2 (Reuters) - Monthly injections of Roche Holding AG's Lucentis can significantly improve sight in people with retinal vein occlusion, which leads to vision loss, according to ...

Retinal artery occlusion was associated with a 1.56-fold increased risk for acute coronary syndrome (relative risk [RR], 1.56; 95% CI, 1.22-1.99) and a twofold increased risk for all-cause mortality ...

Central retinal artery occlusion (CRAO) is a medical emergency, and systems of care need to evolve to enable prompt recognition, triage, and management in a manner similar to that of cerebral ischemic ...